A Randomised, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc (MVC) as a Switch for Either Nucleoside or Nucleotide Analogue Reverse Transcriptase Inhibitors (N(t)RTI) or Boosted Protease Inhibitors (PI/r) in HIV-1 Infected Individuals With Stable, Well-controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of Combination Antiretroviral Therapy (cART)

Trial Profile

A Randomised, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc (MVC) as a Switch for Either Nucleoside or Nucleotide Analogue Reverse Transcriptase Inhibitors (N(t)RTI) or Boosted Protease Inhibitors (PI/r) in HIV-1 Infected Individuals With Stable, Well-controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of Combination Antiretroviral Therapy (cART)

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2016

At a glance

  • Drugs Maraviroc (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms MARCH
  • Most Recent Events

    • 05 Apr 2016 Primary endpoint of comparison of the switch arms to control arm of proportions of participants with HIV RNA 200 copies/mL 48 weeks after randomisation has not been met, according to results published in the Clinical Infectious Disease.
    • 05 Apr 2016 Results (n=395) published in the Clinical Infectious Diseases
    • 19 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top